SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

NeuroStar

STIM·Neuronetics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved / Commercialized
Time to market
Already commercialized. NeuroStar has been FDA-cleared and marketed since 2008 for adult MDD, with additional indications (OCD, adolescent MDD, anxious depression) added through subsequent 510(k) clearances, most recently in March 2024.
Why 4/10
NeuroStar is already FDA-cleared and commercially marketed across multiple indications with no pending PDUFA date, pivotal readout, or Advisory Committee meeting scheduled in the next 12 months. The defining binary events (FDA clearances) have already passed. As a result, impactScore is capped at 4 per the rubric for approved, commercial-stage products with no imminent regulatory binary.
Actionable Insight NEUTRAL

The next catalyst for STIM is the Q4 2026 earnings report, expected in early February 2027, which will show whether the company can sustain its return to operating profitability and positive adjusted EBITDA. The integration of the TrakStar platform with AdvancedMD (scheduled for Q4 2026) and any updates on the Greenbrook clinic expansion and COMP360 collaboration readiness are also worth watching. There is no binary FDA decision or pivotal readout on the horizon since NeuroStar is already fully commercialized.

Price Chart

Loading chart...

Executive Summary

NeuroStar Advanced Therapy is a transcranial magnetic stimulation (TMS) system developed by Neuronetics, Inc. (NASDAQ: STIM) for treating major depressive disorder and other psychiatric conditions. It is already FDA-cleared for multiple indications including adult MDD (since 2008), MDD with anxious depression, obsessive-compulsive disorder, and adolescent MDD (ages 15-21, cleared March 2024). The company is a commercial-stage medical technology firm that also operates the Greenbrook network of interventional psychiatry clinics. In Q3 2026, Neuronetics reported $42M in revenue (+12.5% YoY), returned to operating profitability with $541K in operating income, and generated $1.9M in positive adjusted EBITDA. The stock trades around $2.43 with a market cap of roughly $172M, well below the analyst mean price target of $5.75. There are no pending FDA decisions or pivotal trial readouts, making this a commercial execution story rather than a binary catalyst play.

How It Works

NeuroStar uses transcranial magnetic stimulation (TMS), a non-invasive procedure that delivers focused magnetic pulses through a coil placed on the scalp. These pulses stimulate underactive nerve cells in the region of the brain that controls mood. The treatment is drug-free, does not require sedation or anesthesia, and patients remain awake and alert during the session. A typical course involves daily sessions over several weeks.

Trial Status

NeuroStar is already FDA-cleared and commercially available across multiple indications. The company continues to generate real-world evidence through its TrakStar database and presented data at the CTMSS 2026 conference. The Greenbrook clinic network is expanding, and the company has a research collaboration with Compass Pathways to develop delivery models for COMP360 psilocybin treatment if FDA-approved.

The Two-Sided Case

▲ Bull Case5
NeuroStar is the leading TMS system for depression with over 6.1 million treatments delivered and the largest clinical dataset of any TMS system, backed by FDA clearances across MDD, anxious depression, OCD, and adolescent MDD.
The company returned to operating profitability in Q3 2026 with $541K in operating income and $1.9M in positive adjusted EBITDA, a significant improvement from a $7.3M operating loss a year earlier.
Analyst consensus is strongly bullish: 9 Buy/Strong Buy ratings vs. 1 Hold and 0 Sell, with a mean price target of $5.75, implying roughly 112% upside from the recent $2.43 close.
A 10% owner (Jorey Chernett) made open-market purchases of 18,000 shares at $2.27 in late October 2026, signaling insider confidence near recent lows.
The Greenbrook clinic network (up 20.1% YoY in Q3) provides a vertical integration strategy and a path to capture more of the treatment value chain, and the collaboration with Compass Pathways on COMP360 psilocybin delivery could open a new growth avenue if that drug is approved.
▼ Bear Case5
Revenue growth is slowing in the core NeuroStar system business (only +1.8% in Q3 2026), with Greenbrook clinic revenue (+20.1%) doing the heavy lifting, which shifts the revenue mix and raises questions about the durability of the device sales model.
Major institutional holders including BlackRock (-74% of shares), State Street (-65%), and Geode Capital (-52%) all trimmed their STIM positions significantly in Q2 2026, signaling a lack of conviction from large passive and active managers.
The TMS market faces growing competition from BrainsWay (Deep TMS), MagVenture, and Magstim, and competitors have also received FDA clearance for adolescent MDD, eroding NeuroStar's first-mover advantage in that demographic.
The company carries approximately $61M in debt against a market cap of roughly $172M, and while cash burn has improved, the company still reported a net loss of $1.7M in Q3 2026.
The stock dropped ~10% on November 5, 2026, the day after reporting Q3 earnings that beat estimates, suggesting the market was disappointed with the maintained full-year guidance or the revenue mix shift.

Upcoming Catalysts

  • Q4 2026 / full-year 2026 earnings report (expected early February 2027) - will show whether operating profitability and positive adjusted EBITDA are sustainable
  • TrakStar integration with AdvancedMD practice management platform (scheduled for Q4 2026 availability) - could drive NeuroStar system sales by reducing administrative burden for providers
  • Updates on COMP360 psilocybin collaboration with Compass Pathways - Compass reported positive Phase 3 results in February 2026, and FDA approval could create a new growth avenue for Greenbrook clinics
  • Greenbrook clinic expansion updates - the National Center of Excellence opened in July 2026 could serve as a blueprint for further clinic growth

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Neuronetics, Inc. 8-K STIM ·Originating report

Sources · 11

Hover a chip for the title
1 ir.neuronetics.com2 accessdata.fda.gov3 marketbeat.com4 stockanalysis.com5 ir.neuronetics.com6 ir.neuronetics.com7 ir.neuronetics.com8 sec.gov9 koalagains.com10 gurufocus.com11 valye.com